Prestige EHV 1&4 | Biologicals | Products

You have JavaScript disabled

This may result in reduced functionality and affect the graphical presentation of this site.
However, all content will still be available.

View Product label

Vaccine

Prestige^® EHV 1&4

Indications

This product has been shown to be effective for the vaccination of healthy horses 6 months of age or older against EHV-1 and EHV-4. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov. This product has been shown to be effective against virus shredding of EHV‐1 and EHV‐4.

Purpose

Science

Administration

The Science of Advance

EHV-1 and EHV-4, or rhino, can cause respiratory tract infections. EHV 4 is typically associated with upper respiratory disease in younger horses. EHV-1 can cause respiratory disease, late-term abortions, early foal deaths, neurologic disease
A combination of inactivated, purified, concentrated, adjuvanted, equine tissue culture origin equine herpesviruses types 1 and 4 (EHV-1 and EHV-4).
Exceptional safety profile with the smooth Havlogen^® adjuvant
Advanced filtration process through the Antigen Purification System (APS^™)

Science

Additional Resources

EQUINE PRODUCT REFERENCE GUIDE

Administration

Dose:

For primary vaccination aseptically administer 1 mL intramuscularly, repeat with a single dose in 4 - 6 weeks. Historically, annual revaccination with this product has been recommended. The need for this booster has not been established. For more information on revaccination frequency, consult your veterinarian.